Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javier Cubero

Showing results (91-100 of 120) with videos related to

Pageof 12
Sort By:
Biochimica Et Biophysica Acta. Molecular Basis of Disease|February 3, 2023
Lack of Cyclin E1 in hepatocytes aggravates ethanol-induced liver injury and hepatic steatosis in experimental murine model of acute and chronic alcohol-associated liver diseasePierluigi Ramadori, Marius Maximilian Woitok, Olga Estévez-Vázquez, et al.
Journal of Hepatology|May 4, 2024
Control compounds for preclinical drug-induced liver injury assessment: Consensus-driven systematic review by the ProEuroDILI networkAntonio Segovia-Zafra, Marina Villanueva-Paz, Ana Sofia Serras, et al.
Metabolites|February 25, 2022
A Potential Role for Bile Acid Signaling in Celiac Disease-Associated Fatty LiverPaul Manka, Svenja Sydor, Julia M Schänzer-Ocklenburg, et al.
Scientific Reports|August 16, 2017
Krüppel-like factor 6 is a transcriptional activator of autophagy in acute liver injurySvenja Sydor, Paul Manka, Jan Best, et al.
Journal of Hepatology|June 25, 2021
Advanced preclinical models for evaluation of drug-induced liver injury - consensus statement by the European Drug-Induced Liver Injury Network [PRO-EURO-DILI-NET]Jose C Fernandez-Checa, Pierre Bagnaninchi, Hui Ye, et al.
Gastroenterologia Y Hepatologia|March 6, 2022
Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH)Rocío Gallego-Durán, Agustín Albillos, Javier Ampuero, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 5, 2021
Anti-TNFα treatment in Crohn's disease: Impact on hepatic steatosis, gut-derived hormones and metabolic statusPaul Manka, Svenja Sydor, Nishikant Wase, et al.
Nature Communications|January 9, 2026
Identification of ACBP as a potential target in ciliopathic obesity through multi-omics network analysisYaiza Corral Nieto, Amanda Gabrielly Fernández Pereira, Laura Ventura-San Pedro, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 8, 2021
Liver fibrosis in patients with metabolic associated fatty liver disease is a risk factor for adverse outcomes in COVID-19Alejandro Campos-Murguía, Berenice Monserrat Román-Calleja, Israel Vicente Toledo-Coronado, et al.
Cell Death & Disease|February 11, 2022
Genetic and pharmacological inhibition of XBP1 protects against APAP hepatotoxicity through the activation of autophagyHui Ye, Chaobo Chen, Hanghang Wu, et al.
Pageof 12

Showing results (91-100 of 120) with videos related to

Sort By:
Pageof 12
Biochimica Et Biophysica Acta. Molecular Basis of Disease|February 3, 2023
Lack of Cyclin E1 in hepatocytes aggravates ethanol-induced liver injury and hepatic steatosis in experimental murine model of acute and chronic alcohol-associated liver diseasePierluigi Ramadori, Marius Maximilian Woitok, Olga Estévez-Vázquez, et al.
Journal of Hepatology|May 4, 2024
Control compounds for preclinical drug-induced liver injury assessment: Consensus-driven systematic review by the ProEuroDILI networkAntonio Segovia-Zafra, Marina Villanueva-Paz, Ana Sofia Serras, et al.
Metabolites|February 25, 2022
A Potential Role for Bile Acid Signaling in Celiac Disease-Associated Fatty LiverPaul Manka, Svenja Sydor, Julia M Schänzer-Ocklenburg, et al.
Scientific Reports|August 16, 2017
Krüppel-like factor 6 is a transcriptional activator of autophagy in acute liver injurySvenja Sydor, Paul Manka, Jan Best, et al.
Journal of Hepatology|June 25, 2021
Advanced preclinical models for evaluation of drug-induced liver injury - consensus statement by the European Drug-Induced Liver Injury Network [PRO-EURO-DILI-NET]Jose C Fernandez-Checa, Pierre Bagnaninchi, Hui Ye, et al.
Gastroenterologia Y Hepatologia|March 6, 2022
Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH)Rocío Gallego-Durán, Agustín Albillos, Javier Ampuero, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 5, 2021
Anti-TNFα treatment in Crohn's disease: Impact on hepatic steatosis, gut-derived hormones and metabolic statusPaul Manka, Svenja Sydor, Nishikant Wase, et al.
Nature Communications|January 9, 2026
Identification of ACBP as a potential target in ciliopathic obesity through multi-omics network analysisYaiza Corral Nieto, Amanda Gabrielly Fernández Pereira, Laura Ventura-San Pedro, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 8, 2021
Liver fibrosis in patients with metabolic associated fatty liver disease is a risk factor for adverse outcomes in COVID-19Alejandro Campos-Murguía, Berenice Monserrat Román-Calleja, Israel Vicente Toledo-Coronado, et al.
Cell Death & Disease|February 11, 2022
Genetic and pharmacological inhibition of XBP1 protects against APAP hepatotoxicity through the activation of autophagyHui Ye, Chaobo Chen, Hanghang Wu, et al.
Pageof 12